Dateline City:
KENILWORTH, N.J.
Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that a Phase 2 study of relebactam, the companys
investigational beta-lactamase inhibitor, in combination with
imipenem/cilastatin (an approved carbapenem antibiotic), in patients
with complicated urinary tract infections, met its primary endpoint.
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558orRobert Consalvo, (908) 295-0928orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more